Navigation Links
InterMune Announces Presentations of New Research in IPF at ERS
Date:8/27/2012

ith Idiopathic Pulmonary Fibrosis Receiving Commonly Used Concomitant Medications"
Location: Hall A11/P718

Monday, September 3, 2012
14:45 - 16:45 h
Oral Presentation
Dr. Ulrich Costabel:  "Analysis of Lung Function and Survival in RECAP: An Open-label Extension Study of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis"
Location: Oral Presentation OP2820/Hall A3

Tuesday, September 4, 2012
08:30 - 10:30 h
Poster Discussion
Dr. Dominique Valeyre:  "The Long-term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis: Integrated Analysis of Safety from Four Clinical Trials"
Location: Hall A5/P3159

12:50 - 14:40 h
Poster Presentation
Dr. Steve Nathan:  "6-Minute Walk Test in Patients with Idiopathic Pulmonary Fibrosis: Confirmation of the Minimal Clinically Important Difference"
Location: Hall A13/P3656

About RECAP
RECAP is an open-label extension study for patients who participated in the Phase 3 program for Esbriet, known as CAPACITY.  The CAPACITY program (studies 004 and 006) was designed to evaluate the safety and efficacy of Esbriet in IPF patients with mild to moderate impairment in lung function. In the CAPACITY studies, 779 patients were randomized to treatment with Esbriet or placebo and 626 patients completed the study.  Of these, 603 (96 percent) were enrolled in RECAP. 

Long-term safety results from RECAP were initially presented at the Annual Congress of the European Respiratory Society (ERS) in September 2011.  These results demonstrated that long-term treatment with Esbriet was safe and generally well-tolerated, with a long-term safety profile similar to that observed in CAPACITY.

About Esbriet® (pirfenidone)
Esbriet is an orally active drug that inhibits the synthesis of TGF-beta, a chemical mediator that controls many cell functions including proliferation
'/>"/>

SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. InterMune to Divest Actimmune® (Interferon Gamma-1b)
2. InterMune Reports Second Quarter 2012 Financial Results and Business Highlights
3. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
4. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
5. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
6. Misonix Announces New Distribution Agreement For Panama
7. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
8. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
9. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
10. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
11. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... BURLINGTON, Mass. , July 22, 2014  Decision Resources ... in Canada will remain relatively stagnant ... is despite the fact that percutaneous coronary intervention (PCI) volumes ... to other developed markets, such as the United ... growth will be largely driven by the increase in penetration ...
(Date:7/22/2014)... July 22, 2014 According ... "Process Spectroscopy Market (Technology Types - Near infrared (NIR) spectroscopy, ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 ... in 2012 and is expected to grow at a CAGR ... North America was the largest contributor to global ...
(Date:7/22/2014)... 2014  Eyeon Therapeutics has received a Notice of ... a charged hydrophilic polymer developed at Particles Sciences, a ... to be safe and effective in a small trial ... "This first set of claims around the polymer and ... this technology into the commercial phase.  We have been ...
Breaking Medicine Technology:The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 2The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 3Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 2Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 3Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 4Particle Sciences and Eyeon Therapeutics Receive Patent on Novel Dry Eye Technology 2
(Date:7/22/2014)... undergoing a minimally invasive hysterectomy using electric power morcellation, ... at the time of the procedure, according to a ... concern that this procedure, in which the uterus is ... of undetected malignancies. , Despite the commercial availability of ... the prevalence of malignancy at the time of electric ...
(Date:7/22/2014)... of Hematology (ASH) will present the Society,s highest honor, ... in Hematology, to Kanti R. Rai, MD, of the ... for his 50-year career combining landmark clinical leukemia research, ... care. , The Wallace H. Coulter Award for ... who has been a vital contributor to the field ...
(Date:7/22/2014)... mechanisms with cancer, according to a new report by ... , published in PLOS ONE on July ... very same inhibitors of apoptosis, or cell destruction, in ... diseases. Henry Kaminski, M.D. , chair of the ... and Health Sciences (SMHS), as well as colleagues from ...
(Date:7/22/2014)... Ticket Down is a reliable source ... Fedex Field in Landover, MD. There has never been a ... international soccer. After the success of the American national soccer team ... and well. One way that fans of the world’s sport will ... the 2014 Guinness International Champions Cup. The tournament will kick off ...
(Date:7/22/2014)... The market for botulinum neurotoxin (BoNT) products has ... novel medical indications created and due to more cosmetic ... physical appearance is extremely valued. Although the BoNT market ... companies and technologies are setting ground for biosuperiors and ... price of 1st-gen products under pressure, only innovation is ...
Breaking Medicine News(10 mins):Health News:Study examines presence of uterine cancers at the time of hysterectomy using morcellation 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 3Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 4Health News:New research finds pathogenic connection between autoimmune disorders and cancer 2Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 2Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 3Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 2Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 3Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 4
... April 24 Actavis Group, the,international generic pharmaceuticals ... a case study on the Company and its ... Actavis, ,Winning,formula," was presented in an MBA class ... will be made available to business,schools around the ...
... Was Served, -, LOS ANGELES, April 23 ... against Yolanda McGriff, a Los Angeles-,based healthcare worker who ... a low-income, disabled veteran. McGriff was arrested for,trespass-related violations ... employer, a man who lived in what used to ...
... Reflecting the growing concern,over health care costs and ... afford a comfortable retirement decreased over the past ... of the Retirement Confidence Survey(R),(RCS), according to just-released ... News Release, go to:, http://www.prnewswire.com/mnr/ebri/32335/ , The ...
... of image-guided ... therapy, PALO ALTO, Calif., April 23 Varian Medical,Systems ... than 60 orders for,its new RapidArc radiotherapy product for faster ... but have also come in from Europe and Asia,since the ...
... the voice of the,public, Hero Nutritionals, Inc. is launching ... adults. Hero Nutritionals, manufacturer of Yummi,Bears, the original gummy ... moms buying Yummi Bears, for an adult version of ... Yummi Bears is the,nation,s #1 & best tasting gummy ...
... using a bionic boot found that during walking, the ankle ... of energy compared to isolated muscles---in other words, the spring ... efficiently. , While much has been done measuring the efficiency ... measure the energy efficiency of a body part such as ...
Cached Medicine News:Health News:Harvard Business School Publishes a Case Study on Robert Wessman and Actavis 2Health News:Harvard Business School Publishes a Case Study on Robert Wessman and Actavis 3Health News:Case Dropped Against Healthcare Worker Who Was Arrested While Providing Care to an Elderly, Disabled Man in Los Angeles Home 2Health News:Video: 18th Annual Retirement Confidence Survey(R): Health Care, Economy Major Concerns in Workers' Record Drop in Retirement Confidence 2Health News:Video: 18th Annual Retirement Confidence Survey(R): Health Care, Economy Major Concerns in Workers' Record Drop in Retirement Confidence 3Health News:Video: 18th Annual Retirement Confidence Survey(R): Health Care, Economy Major Concerns in Workers' Record Drop in Retirement Confidence 4Health News:Varian Medical Systems Announces Record Demand for New RapidArc(TM) Radiotherapy Treatment Capability 2Health News:Varian Medical Systems Announces Record Demand for New RapidArc(TM) Radiotherapy Treatment Capability 3Health News:Varian Medical Systems Announces Record Demand for New RapidArc(TM) Radiotherapy Treatment Capability 4Health News:Varian Medical Systems Announces Record Demand for New RapidArc(TM) Radiotherapy Treatment Capability 5Health News:Hero Nutritionals Introduces a New Adult Vitamin for the Taste Buds 2Health News:The spring in your step is more than just a good mood 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: